ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,883,709 | +31.9% | 290,483 | +49.4% | 0.01% | +42.9% |
| Q2 2023 | $5,977,608 | -18.0% | 194,457 | -3.9% | 0.01% | -22.2% |
| Q1 2023 | $7,289,337 | -8.4% | 202,313 | +0.5% | 0.01% | -10.0% |
| Q4 2022 | $7,956,048 | +3.1% | 201,317 | +5.2% | 0.01% | 0.0% |
| Q3 2022 | $7,720,000 | -10.8% | 191,429 | -7.0% | 0.01% | 0.0% |
| Q2 2022 | $8,651,000 | +32.1% | 205,777 | +22.5% | 0.01% | +66.7% |
| Q1 2022 | $6,547,000 | -1.9% | 168,035 | +0.4% | 0.01% | 0.0% |
| Q4 2021 | $6,671,000 | +19.5% | 167,407 | +8.4% | 0.01% | 0.0% |
| Q3 2021 | $5,583,000 | -6.0% | 154,492 | -0.6% | 0.01% | 0.0% |
| Q2 2021 | $5,940,000 | -11.0% | 155,492 | +1.6% | 0.01% | -14.3% |
| Q1 2021 | $6,674,000 | -9.4% | 152,992 | +3.9% | 0.01% | -22.2% |
| Q4 2020 | $7,367,000 | -32.4% | 147,192 | -43.1% | 0.01% | -40.0% |
| Q3 2020 | $10,892,000 | +18.8% | 258,891 | +37.1% | 0.02% | +15.4% |
| Q2 2020 | $9,171,000 | – | 188,891 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |